What Are the Risks of Regenerative Medicine?

Regenerative medicine — a category that includes stem cell therapy, exosome therapy, and platelet-rich plasma (PRP) — carries risks that range from ordinary injection-site soreness to serious, sometimes fatal, complications. Most of the well-documented harm traces back to products marketed directly to consumers without FDA oversight, not to regenerative medicine as a field (FDA, 2026; Bauer et al., 2018). A physician evaluation, an honest look at what the evidence does and doesn't support, and a clear understanding of a product's regulatory status are the tools available to manage that risk. This article lays out what's actually known.

What This Means

The FDA regulates products made from human cells or tissues. A small number of cellular and biologic products have gone through FDA review and hold approval for specific, narrow indications. A separate, much larger category — same-day, minimally manipulated procedures performed by a physician using a patient's own tissue — can fall under a narrow regulatory exception rather than requiring individual product approval. Outside those two categories, most stem cell and exosome procedures marketed directly to consumers for orthopedic, neurological, or anti-aging purposes have not gone through FDA review at all (FDA, 2026). That distinction — approved, exempted, or unreviewed — is the single most important piece of information for evaluating risk, and it's rarely explained clearly in marketing materials.

Candidacy

Regenerative medicine consultations are a reasonable next step for people with a musculoskeletal or joint-related condition who have already explored conventional options and want to understand whether a physician-guided regenerative option fits their specific case. They are a poor fit for people with an active infection, certain current or past cancers (tumor formation is a documented risk factor in the research), pregnancy, a bleeding disorder, or an expectation of a guaranteed outcome. Only a physician exam can sort out which category a given person falls into — marketing copy can't.

Clinical Evaluation

A responsible evaluation includes a physical exam, a review of prior imaging and records, lab work when indicated, and a conversation about the regulatory status of whatever product is being proposed. It should also include a written informed-consent document that states plainly whether the procedure is investigational, a discussion of conventional alternatives, and a clear breakdown of cost — since most regenerative procedures are paid out of pocket rather than covered by insurance.

Available Options

Conventional, well-established options for musculoskeletal and joint conditions include physical therapy, oral or topical anti-inflammatory medication, corticosteroid injection, bracing, and, when appropriate, surgery. Regenerative options include platelet-rich plasma (PRP), which uses a patient's own concentrated platelets, and cellular or exosome-based procedures. Many marketed uses of stem cell and exosome procedures — particularly for orthopedic, neurological, or anti-aging purposes — fall outside an FDA-cleared indication and are considered investigational (FDA, 2026). A physician should lay out both the conventional and regenerative paths, not just the one being sold.

Benefits, Limitations and Risks

Benefits: small, controlled trials of mesenchymal stem cell (MSC) procedures have generally reported a low rate of serious toxicity, and some patients report symptom improvement — though results vary by individual and are not guaranteed (Leonov et al., 2025).

Limitations: evidence quality varies widely across procedure types and products; outcomes are not standardized between clinics; most procedures are cash-pay and not refundable if results are disappointing.

Risks: common, usually minor reactions include injection-site soreness, swelling, or bruising. Less common risks include infection, an unwanted immune response, and — rarely — tumor formation (Leonov et al., 2025). For unapproved, direct-to-consumer products specifically, peer-reviewed case reviews and FDA reports document serious, sometimes fatal harm, including sepsis, organ failure, and blindness (Bauer et al., 2018; Pew Charitable Trusts, 2021; FDA, 2026). None of this is minor, and none of it should be waved off.

What the Evidence Shows

The evidence does establish that FDA-approved cellular procedures — bone marrow transplantation, for example — have decades of safety data behind them, and that small research trials of MSC-based procedures in controlled settings generally report a low rate of serious toxicity (Leonov et al., 2025; Terzic & Nelson, 2013).

The evidence does not establish that stem cell or exosome procedures marketed for orthopedic, anti-aging, or neurological purposes outside an FDA-cleared indication reliably produce a specific outcome, and long-term safety data for most direct-to-consumer products simply doesn't exist yet. A 2018 review of case reports found 35 serious complications tied to unproven stem cell interventions, 10 of them fatal, and a broader 2021 review documented hundreds of adverse events reported between 2004 and 2020 — concentrated almost entirely in unapproved, non-FDA-regulated settings (Bauer et al., 2018; Pew Charitable Trusts, 2021).

Recovery and Next Steps

Recovery depends on the specific procedure performed. Mild soreness and swelling for a few days after an injection-based procedure is common and typically resolves on its own. Fever, spreading redness, or pain that worsens instead of improving are reasons to contact your physician promptly rather than wait it out. Adverse events tied to a specific product can also be reported directly to the FDA's MedWatch program, which is how much of the case data cited in this article was collected in the first place.

Orlando Considerations

Florida physician licensure can be verified directly through the Florida Board of Medicine's public license-lookup tool before scheduling an appointment. It's reasonable to ask, in advance and in writing, exactly what product is being proposed and whether it falls under an FDA-cleared pathway or the narrow same-day, minimally manipulated autologous exception described above. A provider who can't answer that clearly is a red flag on its own.

Frequently Asked Questions

Is regenerative medicine FDA-approved?

A small number of cellular and biologic products are FDA-approved for specific, narrow indications. Most stem cell and exosome procedures marketed for orthopedic, neurological, or anti-aging purposes are used outside an FDA-cleared indication and are considered investigational (FDA, 2026).

What's the most common side effect?

Injection-site soreness, swelling, or bruising is the most frequently reported reaction, and it typically resolves within a few days.

Can regenerative medicine procedures cause serious harm?

Yes. Peer-reviewed case reviews have documented serious complications — including infection, organ damage, and death — almost entirely tied to unapproved products used outside FDA oversight (Bauer et al., 2018).

How do I know if a provider is legitimate?

Confirm the physician's Florida license, ask specifically what product is being used and its regulatory status, and expect a real physical exam — not a same-day sales pitch — before anything is scheduled.

Does insurance cover regenerative medicine?

Most regenerative medicine procedures are considered investigational or elective and aren't covered by insurance. Ask for a full cost breakdown in writing before moving forward.

This article is for general educational purposes and doesn't replace a one-on-one medical evaluation. Regenerative medicine procedures, including stem cell therapy and exosome therapy, are considered investigational for most uses outside FDA-cleared indications. Individual results vary, and options are discussed only after a physician evaluation.

Medically reviewed by Kenny Chantasi, DO.

References

Bauer, G., Elsallab, M., & Abou-El-Enein, M. (2018). Concise review: A comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions. Stem Cells Translational Medicine, 7(9), 676–685. https://doi.org/10.1002/sctm.17-0282

Center for Biologics Evaluation and Research. (2026). Patient and consumer warning about potential serious risks of harm following use of unapproved products from human cells or tissues. U.S. Food and Drug Administration. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/patient-and-consumer-warning-about-potential-serious-risks-harm-following-use-unapproved-products

Leonov, G. E., Grinchevskaya, L. R., Makhnach, O. V., Samburova, M. V., Goldshtein, D. V., & Salikhova, D. I. (2025). Safety assessment of stem cell-based therapies: Current standards and advancing frameworks. Cells, 14(21), 1660. https://doi.org/10.3390/cells14211660

Pew Charitable Trusts. (2021). Harms linked to unapproved stem cell interventions highlight need for greater FDA enforcement. https://www.pew.org/en/research-and-analysis/issue-briefs/2021/06/harms-linked-to-unapproved-stem-cell-interventions-highlight-need-for-greater-fda-enforcement

Terzic, A., & Nelson, T. J. (2013). Regenerative medicine primer. Mayo Clinic Proceedings, 88(7), 766–775. https://doi.org/10.1016/j.mayocp.2013.04.017

Last medically reviewed: September 09, 2026

Related reading

• How Do You Know If You’re a Good Candidate for Regenerative Medicine?
• What Conditions Can Regenerative Medicine Treat?
• How to Compare Orlando Regenerative Clinics
• How Long Does Regenerative Medicine Take to Work?

More questions answered on the PrimeCell patient blog, or see frequently asked questions.

Related services at PrimeCell

PrimeCell is a physician-led practice in Orlando. Candidacy for any procedure is determined at an in-person evaluation.